Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Shares Issued (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Shares Issued for 17 consecutive years, with -$2.7 million as the latest value for Q4 2025.

  • Quarterly Shares Issued rose 10.0% to -$2.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.7 million through Dec 2025, down 290.0% year-over-year, with the annual reading at $6.0 million for FY2023, 4.76% down from the prior year.
  • Shares Issued for Q4 2025 was -$2.7 million at Myriad Genetics, up from -$3.0 million in the prior quarter.
  • The five-year high for Shares Issued was $39.9 million in Q3 2021, with the low at -$90.0 million in Q4 2021.
  • Average Shares Issued over 5 years is $600000.0, with a median of $2.4 million recorded in 2022.
  • Peak annual rise in Shares Issued hit 8733.33% in 2021, while the deepest fall reached 5100.0% in 2021.
  • Over 5 years, Shares Issued stood at -$90.0 million in 2021, then soared by 102.67% to $2.4 million in 2022, then skyrocketed by 150.0% to $6.0 million in 2023, then crashed by 150.0% to -$3.0 million in 2024, then grew by 10.0% to -$2.7 million in 2025.
  • According to Business Quant data, Shares Issued over the past three periods came in at -$2.7 million, -$3.0 million, and $6.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.